国药控股(01099)：国药一致(000028.SZ)前三季度归母净利为约10.66亿元同比下降10.43%

智通财经10-22

智通财经APP讯，国药控股(01099)公布国药一致(000028.SZ)2024年度前三季度业绩快报，实现营业收入564.66亿元，同比下降0.21%;归属于上市公司股东的净利润10.66亿元，同比下降10.43%，相应的基本每股收益同比下降10.75%，加权平均净资产收益率同比下降1.19个百分点。2024年第三季度，实现营业收入186.80亿元，同比增长 2.65%;归属上市公司股东的净利润...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2477229331?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-22 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477229331","market":"hk","top_or_hot":-1,"title":"国药控股(01099)：国药一致(000028.SZ)前三季度归母净利为约10.66亿元 同比下降10.43%","media":"智通财经","content":"<div>\n<p>智通财经APP讯，国药控股(01099)公布国药一致(000028.SZ)2024年度前三季度业绩快报，实现营业收入564.66亿元，同比下降0.21%;归属于上市公司股东的净利润10.66亿元，同比下降10.43%，相应的基本每股收益同比下降10.75%，加权平均净资产收益率同比下降1.19个百分点。2024年第三季度，实现营业收入186.80亿元，同比增长 2.65%;归属上市公司股东的净利润...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1197682.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国药控股(01099)：国药一致(000028.SZ)前三季度归母净利为约10.66亿元 同比下降10.43%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国药控股(01099)：国药一致(000028.SZ)前三季度归母净利为约10.66亿元 同比下降10.43%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-22 21:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1197682.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，国药控股(01099)公布国药一致(000028.SZ)2024年度前三季度业绩快报，实现营业收入564.66亿元，同比下降0.21%;归属于上市公司股东的净利润10.66亿元，同比下降10.43%，相应的基本每股收益同比下降10.75%，加权平均净资产收益率同比下降1.19个百分点。2024年第三季度，实现营业收入186.80亿元，同比增长 2.65%;归属上市公司股东的净利润...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1197682.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01099","symbol_name":"国药控股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1197682.html","article_id":"2477229331","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477229331","pubTimestamp":1729602450,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，国药控股 公布国药一致2024年度前三季度业绩快报，实现营业收入564.66亿元，同比下降0.21%;归属于上市公司股东的净利润10.66亿元，同比下降10.43%，相应的基本每股收益同比下降10.75%，加权平均净资产收益率同比下降1.19个百分点。2024年第三季度，实现营业收入186.80亿元，同比增长 2.65%;归属上市公司股东的净利润3.22亿元，同比下降10.39%。零售板块实现营业收入163.97亿元，同比下降7.47%;实现净利润-0.39亿元，同比下降110.36%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01099":"国药控股","LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","BK0196":"行业龙头","BK1500":"做空集合股","BK0185":"二线龙头","BK1515":"抗疫概念","BK0175":"白马股","BK0250":"批发","BK0010":"央企","BK0028":"国家队","BK0188":"融资融券","BK0082":"国资改革","BK1197":"保健护理产品经销商","000028":"国药一致"},"translate_title":"Sinopharm Holdings (01099): Sinopharm Accord (000028. SZ) 's net profit attributable to the parent company in the first three quarters was approximately 1.066 billion yuan, a year-on-year decrease of 10.43%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000028":1,"01099":1},"content_text":"智通财经APP讯，国药控股(01099)公布国药一致(000028.SZ)2024年度前三季度业绩快报，实现营业收入564.66亿元，同比下降0.21%;归属于上市公司股东的净利润10.66亿元，同比下降10.43%，相应的基本每股收益同比下降10.75%，加权平均净资产收益率同比下降1.19个百分点。2024年第三季度，实现营业收入186.80亿元，同比增长 2.65%;归属上市公司股东的净利润3.22亿元，同比下降10.39%。2024年1-9月，分销板块实现营业收入408.36亿元，同比增长 3.20%;实现净利润7.81亿元，同比下降0.91%。主要系应收账款回款延迟，相应的资金成本增加，导致利润下降。零售板块(即“国药控股国大药房有限公司”)实现营业收入163.97亿元，同比下降7.47%;实现净利润-0.39亿元，同比下降110.36%。主要系受门诊统筹等行业政策变化、市场竞争加剧等因素影响，零售板块第三季度业绩仍同比下滑，但随着公司经营策略的调整，在经营团队及各级员工的努力下，零售板块的亏损面已逐步缩窄，第三季度实现净利润-2,467.93万元，环比第二季度增加6,729.39万元，增长率为73.17%。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477229331"}

国药控股(01099)：国药一致(000028.SZ)前三季度归母净利为约10.66亿元 同比下降10.43%

精彩评论

国药控股(01099)：国药一致(000028.SZ)前三季度归母净利为约10.66亿元同比下降10.43%